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Identity 
Other names: C20orf1, C20orf2, DIL-2, DIL2, 
FLS353, GD:C20orf1, HCA519, HCTP4, REPP86, 
p100 




The TPX2 locus is on the q arm of chromosome 20; 
position 30326904 to 30389603, forward strand (NCBI, 
22974). 
Transcription 
The 3685 bp mRNA (NCBI Reference Sequence: 
NM_012112.4) contains 18 exons (16 coding); the 
processed cDNA is of 2244 bp. Ensembl reports the 
existence of a second transcript, containing 1 additional 
exon (ENST00000340513). TPX2 is expressed in 
proliferating cells; the TPX2 transcript was detected at 
high levels in human placenta, thymus and testis, while 
it was barely detectable in brain, heart, lung and 
pancreas (Manda et al., 1999; Wang et al., 2002; Satow 
et al., 2010). 
Pseudogene 








747 aa; MW: 85653 Da. 
Human TPX2 was initially identified as a nuclear 
protein of apparent molecular weight of 100 kDa 
expressed in proliferating cells, and named p100 
(Heidebrecht et al., 1997); it was subsequently re-
isolated in the search for mitotic targets of RanGTP as 
the homolog of X. laevis TPX2 (Gruss et al., 2001). 
Human TPX2 harbours distinct functional domains: 
- TPX2 is a microtubule-associated protein; both the
full length protein and the N-terminus (amino acids 1-
352) are able to bind microtubules in vitro (Schatz e  
al., 2003; Trieselmann et al., 2003). Additional regions 
in the C-terminus of TPX2 are involved in direct or 
indirect binding to microtubules in cells (Trieselmann 
et al., 2003). Domain characterisation of the Xenopus 
homolog also indicates the presence of one or more 
microtubule-binding domains in the N-terminus of 
TPX2; the C-terminal region has no direct affinity for
microtubules but is required for localisation to spindle 
poles (Brunet et al., 2004). 
- A non canonical nuclear localisation signal (NLS) 
centered around amino acids 314-315 (Schatz et al., 
2003) mediates binding of TPX2 to importin alpha. 
Structural work has confirmed the association of the
corresponding residues 284-287 in the Xenopus 
homolog protein to the "minor" NLS-binding site of 
importin alpha and has shown a second region (residu  
327-330 of Xenopus TPX2) contacting the "major" 
NLS-binding site (Giesecke and Stewart, 2010). 
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Figure 1. TPX2 localisation in human cells. Immunofluorescence images of U2OS osteosarcoma cells stained with DAPI (blue), anti-
alpha-tubulin (green) and anti-TPX2 (red) antibodies show the nuclear localisation of TPX2 in interphase and TPX2 association to spindle 
microtubules in different mitotic stages. Scale bar: 10 µm. 
 
- A KEN box (87-89) degradation motif is required for
recognition by APC/CCdh1 (Stewart and Fang, 2005). 
- The N-terminal region (residues 1-43; Bayliss et al., 
2003) is required for the interaction with, and 
activation of, the Aurora-A kinase. 
- An evolutionary conserved region of 35 amino acids 
at the C-terminus has been shown both in Xenopus and 
mouse TPX2 to bind the Eg5 kinesin (Eckerdt et al., 
2008; Ma et al., 2010). 
Expression 
TPX2 is expressed in a cell cycle-regulated manner; it 
appears in S phase and protein levels remain high in G2 
and mitosis, until telophase when TPX2 is down-
regulated via APC/CCdh1-dependent degradation 
(Heidebrecth et al., 1997; Gruss et al., 2001; Stewart 
and Fang, 2005). TPX2 is differentially expressed in 
tumor vs non-transformed cells (see below). 
Localisation 
TPX2 localises to nuclei of interphase cells (S andG2); 
after nuclear envelope breakdown it associates with 
spindle microtubules; in late anaphase and telophase it 
also localises to the spindle mid-zone (Heidebrecht et 
al., 1997; Gruss et al., 2002; Garrett et al., 2002; figure 
1). 
Function 
Spindle assembly: TPX2 is a RanGTP-regulated 
spindle assembly factor (Gruss et al., 2001). An 
important contribution to the understanding of the 
mechanisms through which TPX2 acts in spindle  
assembly has been provided by studies that made use of 
the Xenopus egg extract system (Gruss and Vernos, 
2004 and references therein). 
Evidence obtained in mammalian cells support the 
notion that TPX2 plays a key role in spindle formation 
and function. Mitotic functions of TPX2 are negatively 
regulated by the binding to importin alpha and beta; the 
presence of RanGTP, by dissociating the complex 
between TPX2 and import receptors, induces the 
release of active TPX2 (Gruss et al., 2001). Indeed, 
excess TPX2 is able to rescue spindle pole organisation 
defects induced by importin beta overexpression in 
human cells (Ciciarello et al., 2004), pointing out the 
functional antagonism between TPX2 and import 
receptors in spindle assembly. 
TPX2 acts in spindle organisation by: 
i) its direct ability to induce microtubule assemblies 
and to bundle microtubules (Schatz et al., 2003); 
ii) its targeting function: TPX2 recruits several mitotic 
regulators to the spindle, i.e. the Aurora-A kinase 
(Kufer et al., 2002), the kinesins hklp2 (Vanneste et al., 
2009; Tanenbaum et al., 2009) and Eg5 (Ma et al., 
2011b) and the scaffold attachment factor A (SAF-A; 
Ma et al., 2011a); 
iii) regulation of specific mitotic factors: TPX2 
interacts with the Aurora-A kinase and activates it, by 
stabilising it in the active conformation (Bayliss et al., 
2003); in addition, TPX2 modulates Aurora-A protein 
stability, by counteracting proteasome-dependent 
Aurora-A degradation (Giubettini et al., 2011). TPX2 
also regulates the activity of the Eg5 kinesin: in vitro  
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assays show that TPX2 reduces the rate of Eg5-
dependent microtubule gliding and microtubule-
microtubule sliding (Ma et al., 2011). 
Consistently, its inactivation in cultured mammalian 
cells impairs microtubule nucleation from 
chromosomes, and to a lesser extent from centrosomes,  
as well as organisation of microtubules within the 
spindle and cohesion of spindle poles (Garrett et al., 
2002; Gruss et al., 2002; De Luca et al., 2006; Tulu et 
al., 2006; Bird and Hyman, 2008). 
Neurogenesis in vertebrate brain: Neural progenitor 
cells in the apical-most region of the neuroepithelum, 
or ventricular zone, exhibit interkinetic nuclear 
migration (INM): their nuclei migrate apically in 
synchrony with cell cycle progression, so that mitosis 
occurs at the apical surface of the ventricular zone. 
TPX2 has been recently reported to promote 
interkinetic nuclear migration in mouse neural cells, by 
re-organising apical microtubules during the G2 phase 
(Kosodo et al., 2011). 
DNA damage response (DDR): recent data show that 
TPX2 is involved in DDR to ionising radiations, by 
modulating the levels of γ-H2AX; TPX2 localises to 
DNA double strand breaks and interacts with DDR 
factors such as MDC1 (Neumayer et al., 2012).  
Previous data suggested a link between TPX2 and 
DDR: i) TPX2 is a putative substrate of the ATM/ATR 
kinases, as revealed in a large-scale proteomic 
screening (Matsuoka et al., 2007); ii) a functional 
interplay has been shown between Xenopus TPX2, the 
Aurora-A kinase and the p53 oncosuppressor (Pascreau 
et al., 2009). 
Homology 
TPX2 orthologs have been identified in all classes of 
vertebrates, with Xenopus, mouse and human TPX2 
being the best characterised.  
TPX2-like proteins have been described in plants (Vos 
et al., 2008; Evrard et al., 2009), C. elegans (Ozlü et al., 




The TPX2 gene is located on the long arm of 
chromosome 20, in a region that is frequently amplified 
in cancer. Growing evidence, described in detail in 
sections below, indicate that TPX2 levels are increased 
in tumors and suggest that TPX2 is involved in 
tumorigenesis. An overall evaluation of TPX2 
overexpression in different cancer types can be 
obtained with the Oncomine database 
(www.oncomine.org), which collects data from several 
microarrays; a recent study using Oncomine shows that 
TPX2 is significantly overexpressed in about 25% of 
analyses of tumor vs normal tissues and that it ranks 
among the first 10% overexpressed genes in the vast 
majority of cases (Asteriti et al., 2010).  
Association of increased TPX2 levels, chromosomal 
instability (CIN) and cancer has also been highlighted: 
TPX2 ranked first in a CIN25 signature, the 
overexpression of which is predictive of poor clinical 
outcome (Carter et al., 2006). A TPX2 gene signature 
has also been recently identified as associated with




Analysis of astrocytoma tissue samples showed 
positive TPX2 staining, while TPX2 was not detected 
in normal brain tissues; in addition, TPX2 expression 
levels were higher in high-grade, compared with low-
grade, astrocytomas.  
The median survival of patients correlated with TPX2 
levels, with high TPX2 being associated with overall 
poor survival (Li et al., 2010).  
TPX2 was also identified among 9 genes which are 
significantly overexpressed in grade III vs grade I 
meningiomas (Stuart et al., 2011) and among 14 genes 
with elevated expression in high-risk neuroblastomas 
with 1p loss and MYCN amplification (Ooi et al., 
2012). 
Oral squamous cell carcinoma 
Prognosis 
Expression levels of TPX2 were not related with tumor 
size, lymph node invasion or histopathologic grading 
(Fenner et al., 2005). 
Oncogenesis 
TPX2 expression levels, analysed by RT-PCR 
(Shigeishi et al., 2009a) or immunohistochemistry 
(Fenner et al., 2005), were significantly higher 
compared with normal oral tissues. 
Salivary gland carcinoma 
Oncogenesis 
Levels of TPX2 mRNA were analysed by RT-PCR in 
20 human salivary gland carcinomas compared with 6 
normal submandibular glands and resulted higher in all 
tumor samples (Shigeishi et al., 2009b). 
Lung cancer 
Note 
Human bronchial epithelial cells malignantly 
transformed by anti-BPDE (16HBE-C) displayed 
abnormal levels of phosphorylated TPX2 on tyrosine 
residues (Zhang et al., 2008). 
Prognosis 
Three studies indicate the prognostic value of TPX2 
overexpression in adenocarcinomas (Kadara et al., 
2009; Li et al., 2013) and squamous cell carcinoma 
(Ma et al., 2006): TPX2 expression is associated with 
tumor grade and stage and poor survival rates. In 
particular, TPX2 is among the top genes in prognostic 
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signatures identified as classifiers for overall survival 
of patients (Kadara et al., 2009; Li et al. 2013). 
Oncogenesis 
Several studies report increased TPX2 expression 
levels in primary lung tumors (adenocarcinomas, 
squamous cell carcinoma, small cell carcinoma) and 
lung cancer cell lines, compared to controls (Manda et 
al., 1999; Tonon et al., 2005; Ma et al., 2006; Zhang et 
al., 2008; Kadara et al., 2009; Li et al., 2013). 
Colon cancer 
Oncogenesis 
TPX2 overexpression in colorectal cancer was 
observed by suppression subtractive hybridisation 
(SSH) method applied to a primary stage III rectal 
adenocarcinoma and the matched non-neoplastic 
mucosa (Hufton et al., 1999).  
In addition, protein levels of TPX2 and of its partner 
Aurora-A correlate significantly with chromosome 20q 
DNA copy number status: TPX2 and Aurora-A are 
therefore implicated in the 20q amplicon-driven 
progression of colorectal adenoma to carcinoma 
(Sillars-Hardebol et al., 2012). 
Liver cancer 
Oncogenesis 
The TPX2 transcript is expressed at high levels in 
hepatocellular carcinomas, compared with weak 
expression in paired normal tissues (Wang et al., 2002; 
Satow et al., 2010). 
Pancreatic cancer 
Prognosis 
Increased expression of TPX2 was associated with poor 
survival and significantly correlated with histological 
grade in two independent cohorts (from Germany and 
Maryland; Zhang et al., 2012).  
When cohorts were combined, and stratified by 
resection margin status (positive vs negative), TPX2 
was associated with cancer-specific mortality in 
resection margin-positive patients and with prognosis 
in resection margin-negative patients. 
Oncogenesis 
Low copy-number amplification of TPX2, associated 
with increased mRNA and protein levels, was observed 
in pancreatic cancer cell lines (Warner et al., 2009); the 
TPX2 gene is also included in an amplicon identified 
by microarray analysis of pancreatic ductal 
adenocarcinoma (Tonon et al., 2005). 
Immunohistochemical staining of tissue microarrays 
showed increased TPX2 levels in pancreatic tumors 
compared with the normal counterparts (Warner et al., 
2009; Zhang et al., 2012). 
Ovarian cancer 
Note 
The Aurora-A kinase, which interacts with, and is 
regulated by, TPX2 is also differentially expressed in 
ovarian carcinomas vs adenomas (Scharer et al., 2008). 
Prognosis 
A comparative analysis revealed a stronger (15 to 27 
fold) overexpression of TPX2 in primary ovarian 
carcinomas compared with non-malignant adenomas 
(Scharer et al., 2008). 
Oncogenesis 
A high resolution genome wide copy number analysis 
combined with matching expression data from primary 
epithelial ovarian carcinomas of various histotypes 
showed that TPX2 is among the most significantly 
differentially expressed genes in a chromosome 20 
region frequently amplified in ovarian cancer 
(Ramakrishna et al., 2010). 
Cervical cancer 
Prognosis 
TPX2 expression levels in cervical squamous cell 
carcinoma positively correlate with tumor stage and 
grade, and lymph node metastasis (Chang et al., 2012). 
Oncogenesis 
Copy number increase of chromosome 20q, where the 
TPX2 gene is located, is frequently observed in 
cervical cancers; indeed TPX2 is reported among the 
26 genes that are significantly overexpressed as 
consequence of 20q gain (Scotto et al., 2008). TPX2 
mRNA and protein are highly expressed in cervical 
cancer, while its expression is almost absent in normal 
cervical tissues (Chang et al., 2012). 
Bladder cancer 
Oncogenesis 
RNA microarrays and RT-PCR analyses showed 
significant upregulation of TPX2 in urothelial 
carcinomas of the bladder compared with normal 
urothelium (Zhou et al., 2013). 
Mesothelial tumors 
Prognosis 
Immunostaining of malignant mesothelioma samples 
compared to benign reactive mesothelial hyperplasia 
showed significant overexpression of TPX2 in 
malignant samples, suggesting that TPX2 represents a 
useful marker in this respect (Taheri et al., 2008). 
To be noted 
Note 
Growing evidence highlights the therapeutic potential 
of TPX2 inactivation. Two RNAi-based screenings 
identified TPX2 among essential genes for tumor 
survival and hence the most promising target 
candidates for anti-cancer strategies (Morgan-Lappe et 
al., 2007; Martens-de Kemp et al., 2013). Several 
studies provide direct demonstration of the anti-
proliferative effects of TPX2 inactivation in cancer 
cells of different tumor types (Morgan-Lappe et al., 
2007; Zhang et al., 2008; Warner et al., 2009; Li et al., 
2010; Satow et al., 2010; Chang et al., 2012; Vainio et 
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al., 2012; Martens-de Kemp et al., 2013). In addition, 
TPX2  
inactivation significantly reduced tumor growth in 
xenografts models based on inoculation in nude mice of 
pancreatic or hepatocellular carcinoma cells (Warner et 
al., 2009; Satow et al., 2010). 
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